Unither Pharmaceuticals has completed the purchase of the Novartis site located at Butantã, in São Paulo, Brazil.

Paris (France), 12/07/2022 - Unither Pharmaceuticals, the world's leading manufacturer of sterile unit-dose products, recently acquired the Novartis plant in São Paulo, Brazil, as a new step in its industrial expansion in Brazil.

« This acquisition enables us to benefit from sterile operations in Latin America and to enlarge our offer to multidose ophthalmic containers. We are pleased to welcome the 180 people joining Unither Pharmaceuticals and bring new possibilities to our customers. » explains Eric Goupil, President of Unither Pharmaceuticals.

Unither Pharmaceuticals has a major interest in the fast-growing ophthalmology market. Thus, ongoing investments are being made, including the acquisition of this new plant in Latin America, which allows the company to manufacture ophthalmic healthcare products across four continents (Europe, Asia, North America, and South America).

For more information about the Unither group: www.unither-pharma.com

Press Contact:

Unither Pharmaceuticals
Tel : 01.44.63.51.70
press@unither-pharma.com

3-5 rue Saint Georges
75009 Paris FRANCE

Unither Pharmaceuticals was established in Amiens, France, in 1993 and specialises in the development and manufacturing of liquid single-dose forms (particularly eye drops, saline solutions, and asthma medications in BFS unit doses and OTC and Rx formulations in stick packs) for pharmaceutical companies and generic manufacturers. Currently employing more than 1,600 people in seven manufacturing plants in France, the United States, Brazil and China, Unither Pharmaceuticals expects to achieve sales of €380 million by 2022.

This release was published on openPR.